Monday, March 10, 2014 8:31:09 PM
What is Oncolytic Immuntherapy?
http://www.oncolyticimmunotherapy.com/
http://www.oncolyticimmunotherapy.com/stages/index.html
Engineer
Lyse
Alert
Find
Fight
Why is Amgen studying Oncolytic Immunotherapy for cancer?
Harnesing a virus by gene modification - What is Amgen doing?
"The virus is modified through the insertion, deletion, and/or inactivation of various genes designed to achieve desired effects, including tumor-cell selectivity, antigen presentation, and cytokine expression"
My comments to this... I see this website appearing now as Amgen's start of the education campaign needed to explain Oncolytic Immunotherapy to potential patients in clinical and eventual commercial acceptance with the intention of moving forward into this space with their BioVex purchase several years ago now and continuing clinical program using a modified Herpes Virus. Funny how the timeline of significant events exclude the discovery of Reovirus' potential in the 90s by Patrick Lee and Matt Coffey at Univ of Calgary.
Now what if the virus did not have to be "engineered" or start with a Herpes virus to fight but a natural unmodified Dearing 3 Reovirus being studied by the pioneers in the field, Oncolytics Biotech which was awarded the rights to try to commercialize the Patrick Lee discoveries.
Reovirus is naturally occurring not modified like the virus being studied by Amgen. It is my opinion that Amgen faces additional regulatory hurdles using a genetically modified virus rather than one that is naturally occurring like Reolysin. It may turn out that you can enhance the effects of Oncolytic Immunotherapy by genetically modifying the virus but if your are using a naturally occurring virus like Reolysin you might just be able to do combos of proven adjuncts like some that have been recently reported so the race is on to figure out what works best and what can get approved in the shortest timeframe both short term and planning for long term competitiveness.
Also Oncolytics claims significant patent positions for broad rights in using Oncolytic virus' for the treatment of cancer and specific manufacturing cell growth and purification methods for viruses. See this link. This IP is valuable IMO.
It sure would make sense to me that ONCY may be a purchase target by Amgen and maybe others who want a piece of what could be new Immunotherapy options for cancer with minor flu-like side effects that you really want if you are using it because if you don't get flu-like symptoms it probably is not working for that specific type of cancer! This field looks very exciting but still is unproven to meet FDA approval but is getting closer everyday.
Here is a link to the current Oncolytics Clinical Trial program.
http://www.oncolyticsbiotech.com/clinical-trials/default.aspx
Also a link to Reolysin clinical trials on clinicaltrials.gov is here. - Search Reolysin
Cheers.
onco_investor - All comments are my opinion only. If you are considering learning more please visit the iBox above or for official company information visit www.oncolyticsBiotech.com
Recent ONCY News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 11:01:30 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2024 04:46:58 PM
- Sernova Corp. Announces Appointment of New Chief Executive Officer • GlobeNewswire Inc. • 08/12/2024 11:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2024 09:11:26 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 08/02/2024 09:08:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2024 12:40:34 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2024 04:15:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 08:54:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 08:03:42 PM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 07/25/2024 09:22:38 PM
- Form F-10 - Registration Statement for Securities of certain Canadian Issuers. • Edgar (US Regulatory) • 07/25/2024 08:48:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 05:34:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 04:04:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 05:47:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 03:00:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:06:37 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 08:37:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 08:36:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 04:11:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 05:43:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 09:06:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 06:08:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 05:37:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 06:09:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/14/2024 01:30:16 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM